Chelat-Therapie / Schwermetallausleitung

Metalle aus Industrie, Verkehr, Nahrung, Kosmetik und Kleidung können die Ursache verschiedenster Erkrankungen sein.

Zahlreiche Studien zeigen, dass schon relativ geringe Mengen von Blei, Cadmium, Arsen, Quecksilber etc. das Risiko für Herzinfarkt, Krebs, Bluthochdruck, Autoimmunerkrankungen, Diabetes und neurologische Erkrankungen sowie die Sterblichkeit erhöhen.

Die Chelat-Therapie ist eine weltweit eingesetzte, ausgesprochen sichere Methode zur Ausleitung von Metallen aus dem menschlichen Körper. Dabei handelt es sich um die Behandlung mit den „Chelatkomplexbildner“, die Metalle im Körper binden, um sie wasserlöslich zu machen. Diese so gebundenen Metalle werden dann über Urin und Schweiß ausgeschieden.

Je nach Alter und Beschwerdebild werden rund 10 bis 20 Infusionen durchgeführt. Eine Infusion dauert ca. 1,5-3 Stunden und kann 1-2-mal pro Woche durchgeführt werden.

Bei uns in der Praxis kombinieren wir die Chelat-Therapie mit der Elektrolyt-/Aminosäuren-Injektionslösung.

Die Chelat-Therapie ist mit vielen anderen Therapieformen kombinierbar und auch mit der Gabe von blutverdünnenden Medikamenten vereinbar.

„Die EDTA Chelat-Therapie macht mir als Chemie- und Medizinforscher Sinn. Sie hat eine vernünftige, wissenschaftliche Basis und die Beweise für ihren klinischen Erfolg scheinen stark zu sein.“ Linus Pauling

„Eine akute Metallbelastung ist selten, eine chronische Schwermetallbelastung ist die Regel“ Peter Jennrich, Arzt und Mitglied des International Board of Clinical Metal Toxicology

Internationale wissenschaftliche Studien:

Foreman H: The use of chelating agents for excelerating excretion of radioelements. J Am Pharm Assoc (42): 629, 1953.

Administration. Proceedings of the Society of Experimental Biology and Medicine, 82: 266, 1953

Hart H and Lazlo D: Modification of the distribution and excretion by radioisotopes by chelating agents. Science 118:24, July 1953.

urran CL: Metal chelating agents and hepatic cholesterol synthesis. Proc Soc Exper Biol & Med 88:101, 1955.

Schroeder HA, Menhard EM and Perry HM Jr: Antihypertensive effects of metal binding agents. J Lab & Clin Med 23:416, 1955

Seven MJ: Observations on the dosage of intravenous chelating agents. Antibiotic Med 5:251, 1958

Painter JT and Morrow EJ: Porphyria. Its manifestations and treatment with chelating agents. Texas State J Med 55:811, 1959

Foreman H: Pharmacology of some useful chelating agents. In Seven MJ and Johnson LA (eds): Metal-Binding in Medicine. Philadelphia, JB Lippincott, 1960.

Seven MJ and Johnson LA: Metal Binding in Medicine, JB Lippincott, Phila, 1960.

Seven MJ: Observations on the toxicity of intravenous chelating agents. In: MJ Seven and LA Johnson (Eds). Metal Binding in Medicine JP Lippincot, Phila, 1960

Oser BL: Observations on the chronic ingestion of a chelating agent by rats and dogs. Fed Proc 20(Suppl 10):158, 1961

Schubert J: Radioelement removal by chelating agents: application of mass action laws and other factors. Fed Proc 20(3) Part II Supp#10:206, 1961

Foreman H: Use of chelating agents in treatment of metal poisoning with special emphsis on lead. Fed Proc 20 (Suppl 10):191, 1961.

Foreman H: Summary remarks by the chairman. [Proceedings of a conference on biological apects of metal-binding.] Fed Proc 20 (Suppl 10):257, 1961.

Kebe SR: ACTH and a chelating agent for schizophrenia. West Med 4:46, 1963

Pullman TN, Lavender AR and Forland M: Synthetic chelating agents in clinical medicine. Ann Rev Med 14:175, 1963

Forssman O and Nordqvist P: The action in vitro and in vivo of sodium versenate on the phagocytic activity of neutrophile leukocytes. Acta Haemat 31:289, 1964.

Rutman JZ, Melttzer LE, Kitchell JR, et al: Effect of metal ions on in vitro gluconeogensis in rat kidney cortex slices. Am J Physiol 208:841, 1965

Davis PS and Deller DJ: Effect of orally administered chelating agents EDTA, DTPA and fructose on radioiron absorption in man. Aust Ann Med 16:70, 1967.

Walshe JM: Triethylene tetramine. Lancet, ii 154, 1970

Sincock A: Life extension in the rotifer by application of chelating agents. J Gerontol 30:289, 1975

Catsch A and Harmuth-Hoene AE: Pharmacology and therapeutic applications of agents used in heavy metal poisoning. Pharmac Ther. A, (1):1, 1976.

Klassen CD: Heavy metals and heavy metal antagonists. Goodman and Gilman’s :The Pharmacological Basis of Therapeutics. 6th Ed.: 1634,1980

JENNETTE KW. (1981): The role of metals in carcinogenesis: biochemistry and metabolism. Environ Health Perspect. 40: 233-252.

Cantilewa LR, Klassen CD: The effect of chelating agents on the excretion of endogenous metals. Toxicol Appl Pharmacol 63:344, 1982

Chelation therapy (Diagnostic and therapeutic technology assessment). JAMA 250:672, 1983.

Chelation therapy. Resolution: 66 (I-84). AMA House of Delegates. 1984.

Gotto AM Jr: Chelation therapy in 1984. Texas Medicine, 80:36, 1984

Chelation therapy: a second look. The Harvard Medical School Health Letter, IX:1, 1984.

Chelation therapy. Report of the Council on Scientific Affairs. Report F (I-84). AMA House of Delegates. 1984.

Silverglade A: Chelation clinics. Chest 87:274 1985.

Klassen CD: Heavy metals and heavy metal antagonists, in Gilman AG, Goodman LS, Rall TW, Murad F (eds): The pharmacological Basis of Therapeutics, 7th ed. New York, Macmillan, pp. 1605,1985

Gordon GF: Oral chelation with EDTA. J Holistic Medicine 8(1):79, 1986.

Chelation Therapy Clinic: Chelation therapy – the treatment of choice for relief from and prevention of, cardiovascular and age-related diseases. Aukland, New Zealand, The Chelation Therapy Clinic, 1987.

Tandon SK: Combination therapy: a better approach to chelation in metal intoxication. Plzen.lek.Sborn. Suppl.56:187, 1988

DGPT – DEUTSCHE GESELLSCHAFT FÜR PHARMAKOLOGIE UND TOXIKOLOGIE (1990): Stellungnahme zur Toxizität von Zahnfüllungen aus Amalgam. Beratungskommission Toxikologie der DGPT. Mitteilungen 1990(5): 24-26. Nachdruck: Med Klin 85: 350-352.

Adams WJ and McGee CT: Chelation therapy: a survey of treatment outcomes and selected socio-medical factors. J Adv Med 5(3):189, 1992.

Chelation therapy – An informal summary. Department of Health & Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. Bethesda, Maryland. June 1992.

Handbook of Metal-Ligand Interactions in Biological Fluids. Guy Berthon ed. Marcel Dekker, Inc. N.Y., N.Y. Vol 2. p. 1486, 1995

BUSSELBERG D. (1995): Calcium channels as target sites of heavy metals.Toxicol Lett. 82-83: 255-261.

APOSHIAN HV. (1998): Mobilization of mercury and arsenic in humans by sodium 2,3-dimercapto-1-propane sulfonate (DMPS). Environ Health Perspect. 106(Suppl 4): 1017-1025.

FOURNIE GJ, MAS M, CAUTAIN B et al. (2001): Induction of autoimmunity through bystander effects. Lessons from immunological disorders induced by heavy metals. J Autoimmun. 16(3): 319-326.

BELLES M, ALBINA ML, SANCHEZ DJ et al. (2002): Interactions in developmental toxicology: effects of concurrent exposure to lead, organic mercury, and arsenic in pregnant mice. Arch Environ Contam Toxicol. 42(1): 93-98.

IARC – INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (2004): Overall Evaluations of Carcinogenicity to Humans As evaluated in IARC Monographs Volumes 1-88. International Agency for Research on Cancer, World Health Organization, Lyon, France.

INSTITORIS L, KOVACS D, KECSKEMETI-KOVACS I et al. (2006): Immunotoxicological investigation of subacute combined exposure with low doses of Pb, Hg and Cd in rats. Acta Biol Hung. 57(4): 433-439.

JENNRICH P. (2007): Schwermetalle – Ursache für Zivilisationskrankheiten. CO`MED Verlagsgesellschaft mbH, Hochheim.

HALLAB NJ, CAICEDO M, FINNEGAN A et al. (2008): Th1 type lymphocyte reactivity to metals in patients with total hip arthroplasty. J Orthop Surg. 3: 6.

BORDIGNON V, PALAMARA F, CORDIALI-FEI P et al. (2008): Nickel, palladium and rhodium induced IFN-gamma and IL-10 production as assessed by in vitro ELISpotanalysis in contact dermatitis patients. BMC Immunol. 9: 19.

AL-SALEHI SK. (2009): Effects of bleaching on mercury ion release from dental amalgam. J Dent Res. 88(3): 39-43

IARC – INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (2010): Carbon black, titanium dioxide, and talc. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 93. International Agency for Research on Cancer, World Health Organization, Lyon, France.

JENNRICH P. (2011): Europarat ruft dazu auf, die Umweltbelastung durch Schwermetalle zu reduzieren. COMED 07/2011: 1-5.

DU H, ZHU X, FAN C, XU S, WANG Y, ZHOU Y. (2012): Oxidative damage and OGG1 expression induced by a combined effect of titanium dioxide nanoparticles and lead acetate in human hepatocytes. Environ Toxicol. 27(10): 590-597.

Efficacy of chelation therapy to remove aluminium intoxication. Fulgenzi A, De Giuseppe R, Bamonti F, Vietti D, Ferrero ME. J Inorg Biochem. 2015 Nov;152:214-8. doi: 10.1016/j.jinorgbio.2015.09.007. Epub 2015 Sep 24.

Unusual presentation of arsenic poisoning in a case of celiac disease. Hasanato RM, Almomen AM. Ann Saudi Med. 2015 Mar-Apr;35(2):165-7. doi: 10.5144/0256-4947.2015.165.

EDTA Chelation Therapy to Reduce Cardiovascular Events in Persons with Diabetes. Ouyang P, Gottlieb SH, Culotta VL, Navas-Acien A. Curr Cardiol Rep. 2015 Nov;17(11):96. doi: 10.1007/s11886-015-0656-y. Review.

Rationale for the Successful Management of EDTA Chelation Therapy in Human Burden by Toxic Metals. Ferrero ME. Biomed Res Int. 2016;2016:8274504. Epub 2016 Nov 8. Review.

Chronic lead poisoning in an Iranian opium smoker resident in London. Azizi A, Ferguson K, Dluzewski S, Hussain T, Klein M. BMJ Case Rep. 2016 Nov 1;2016. pii: bcr2016215965. doi: 10.1136/bcr-2016-215965.

Chronic Toxic Metal Exposure and Cardiovascular Disease: Mechanisms of Risk and Emerging Role of Chelation Therapy. Aneni EC, Escolar E, Lamas GA. Curr Atheroscler Rep. 2016 Dec;18(12):81. Review.

Chronic Toxic Metal Exposure and Cardiovascular Disease: Mechanisms of Risk and Emerging Role of Chelation Therapy. Aneni EC, Escolar E, Lamas GA. Curr Atheroscler Rep. 2016 Dec;18(12):81. Review.

An overview of plant-based interventions to ameliorate arsenic toxicity. Susan A, Rajendran K, Sathyasivam K, Krishnan UM. Biomed Pharmacother. 2019 Jan;109:838-852. doi: 10.1016/j.biopha.2018.10.099. Epub 2018 Nov 5. Review.

New Perspectives in Iron Chelation Therapy for the Treatment of Neurodegenerative Diseases. Nuñez MT, Chana-Cuevas P. Pharmaceuticals (Basel). 2018 Oct 19;11(4). pii: E109. doi: 10.3390/ph11040109. Review.